Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neutropenia
New neutropenia research from E.J. Ip and co-researchers described
September 25th, 2008
"The objective of this study was to compare low-dose filgrastim (150 mu g/day subcutaneously) with standard-dose subcutaneous filgrastim (300 mu g/day) or lenograstim (263 mu g/day) in preventing febrile neutropenia and hospitalizations in breast cancer patients receiving the docetaxel-doxorubicin-cyclophosphamide regimen. A single-center retrospective data analysis was performed involving 22 adult women with breast cancer who concurrently received the clocetaxeldoxorubicin-cyclophospharnicle chemotherapy regimen and low-dose filgrastim from March 2004 to February 2007," investigators in the United States report. "Data from this study were compared to previously...
Source: Women's Health Weekly (2008-09-25)
|
